Publications

Klebsiella pneumoniae belonging to ST258 from a New York city hospital carrying KPC-2- and VIM-4-encoding genes: Report from the SENTRY antimicrobial surveillance program, Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Validation of a TREK diagnostic systems dry-form broth microdilution MIC product for testing ceftazidime-avibactam, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Telavancin activity tested against Gram-positive clinical isolates from European hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity for telavancin, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae recovered principally from lower respiratory tract specimens in older adult patients (≥50 years of age) in select European countries (2009-2011), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftobiprole activity tested against bacterial isolates from hospitalized patients with pneumonia in European hospitals and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Polymyxin B: Can we create a better product?, Lead author: Kassamali, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of daptomycin and comparator agents tested against Methicillin-resistant S. aureus and vancomycin-resistant enterococci: Analysis of five-year trends in Europe and USA hospitals (2009-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Linezolid susceptibility surveillance in Europe for 2013: ZAAPS Program (5,076 strains), Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin tested against Gram-positive clinical isolates responsible for documented skin and soft tissue infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Current analysis of oritavancin potency when tested against vancomycin-resistant and -susceptible enterococcal clinical isolates recovered from European medical centres (2009-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin and comparator agents against multidrug-resistant staphylococcal and streptococcal isolates responsible for documented infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial Activity of Ceftobiprole Tested against Staphylococci and Streptococci from European Countries and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of solithromycin tested against serotyped macrolide-resistant Streptococcus pneumoniae collected from medical centers across the USA (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013) when using a revised susceptibility testing method, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftazidime-avibactam activity tested against select Gram-negative organisms from a global surveillance program (2011) in relation to the ceftazidime epidemiologic cut-off value, Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftolozane/tazobactam activity when tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in European hospitals (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against P. aeruginosa isolates from 15 European countries and Israel (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Azole resistance mechanisms found among fluconazole-resistant Candida albicans clinical isolates: Report from the SENTRY antifungal resistance programme, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Evaluation of EUCAST zone diameter breakpoints for Pseudomonas spp., Lead author: Ahman, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

GSK2140944 MIC quality control ranges using a multi-laboratory study design, Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Global prevalence, genetics and clonal relatedness of macrolide resistance in Moraxella catarrhalis (2010-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Characterization of intrinsic Beta-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa from USA hospitals, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

KPC-producing Pseudomonas aeruginosa from the United States: What is next?, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from European hospitals: Results from the SENTRY Program (2010-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Carbapenem-resistant Klebsiella pneumoniae clinical isolate harbouring a blaIMP-4- and qnrS-carrying plasmid, as well as a conjugative blaKPC-2 plasmid, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria. by Pfaller MA, Messer SA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (1): 108-114

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280

Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 443-448

Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. by Sader HS, Castanheira M, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (3): 1684-1692

Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. by Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B and Azie NE published in PLoS One. 2014; 9 (7): e101510

Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. by Marchand-Austin A, Rawte P, Toye B, Jamieson FB, Farrell DJ and Patel SN published in Anaerobe. 2014; 28: 120-125

Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada. by Marchand-Austin A, Memari N, Patel SN, Tang P, Deeks SL, Jamieson FB, Crowcroft NS and Farrell DJ published in Int. J. Antimicrob. Agents. 2014; 44 (1): 82-84

Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2468-2471

Multilocus sequence typing of Mycobacterium xenopi. by Alexander DC, Marras TK, Ma JH, Mirza S, Liu D, Kus JV, Soualhine H, Escuyer V, Warshauer D, Brode SK, Farrell DJ and Jamieson FB published in J. Clin. Microbiol. 2014; 52 (11): 3973-3977

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. by Kohlhoff SA, Huband MD and Hammerschlag MR published in Antimicrob. Agents Chemother. 2014; 58 (12): 7595-7596

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. by Dallow J, Otterson LG, Huband MD, Krause KM and Nichols WW published in Int. J. Antimicrob. Agents. 2014; 44 (6): 552-556

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. by Barriere SL, Farrell DJ, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (4): 327-329

Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012. by Rennie RP and Jones RN published in Can. J. Infect. Dis. Med. Microbiol. 2014; 25 (5): 285-287

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 323-327

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. by Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J and Turnidge J published in Antimicrob. Agents Chemother. 2014; 58 (4): 2006-2012

Detection of NDM-1-producing Enterobacteriaceae in Romania: Report of the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Flonta M, Jones RN and Castanheira M published in J. Med. Microbiol. 2014; 63 (Pt 3): 483-484

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. by Castanheira M, Jones RN and Sader HS published in J. Chemother. 2014; 26 (4): 202-210

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in J. Antimicrob. Chemother. 2014; 69 (6): 1582-1588

Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2434-2437

Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). by Pfaller MA, Flamm RK, Sader HS and Jones RN published in Diag. Microbiol. Infect. Dis 2014; 78 (4): 422-428

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. by Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR and Martin-Mazuelos published in Antimicrob. Agents Chemother. 2014; 58 (2): 916-922

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States 2014. by Mendes RE, Flamm RK, Hogan PA, Ross JE and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (2): 1243-1247

Resistance surveillance program report for selected European nations (2011). by Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 429-436